Clinical Trial Detail

NCT ID NCT03797261
Title A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

acute myeloid leukemia

Therapies

AMG 176 + Venetoclax

Age Groups: adult senior

No variant requirements are available.